Medprin Regenerative Medical Technologies Co., Ltd. (301033.SZ) has officially announced that its research project involving the "absorbable hemostatic fluid gelatin" has recently entered the clinical trial phase.

The medical device is intended for use during surgical procedures as an adjunct to control bleeding when compression, ligation, electrocautery, or other conventional hemostatic methods are ineffective or impractical for managing hemorrhage from small arteries, veins, or capillaries.